Quantifying De-Risking & Investment Timing in Medtech Venture Capital Through a Hidden Markov Framework

Abstract

Venture capital investment timing in medtech is complex because early-stage com- panies in this industry go through a unique sequential de-risking process. Unlike many other sectors, medtech companies progress through distinct layers of technical, clinical, regulatory, reimbursement, and commercial uncertainty, so understanding this evolution of risk is imperative in investment decisions. This thesis provides a framework that quantifies this progression to understand what it implies about in- vestment timing. Using venture capital transaction data from Preqin, a left-to-right Hidden Markov Model is used to represent companies as moving through latent de- risking stages from Seed through Series E, with Exit and Failure treated as absorbing terminal states. The model accounts for noise in the reported funding labels with a hidden layer and treats financing deal size as a covariate that affects transition prob- abilities. Overall, the results show that medtech firms significantly de-risk as they move from their earliest stages to middle stages, but that risk is not meaningfully reduced in later stages. Since later-stage investments generally offer less equity and therefore lower returns, these results suggest that the optimal time to invest may lie in the middle of the venture path.